Merck Licenses Anti-Tau Alzheimer’s Antibody from Teijin Pharma
Posted on29 May 2017
Comments0
Teijin Pharma granted Merck exclusive global rights to develop, manufacture, and commercialize a preclinical-stage anti-tau antibody. Merck says the antibody candidate will... Read More
“Assignment of a TradeMark” – What is that mean?
This is a legal term associated with trademark. When one trademark owner transfer it’s trademark to another party, the term trademark assignment... Read More
Kite Pharma’s axicabtagene got US FDA priority review status to treat NHL
Kite Pharma a leading cell therapy company, has announced that the US Food and Drug Administration (FDA) has accepted for priority review... Read More
Case Study: Ablynx – Merck KGaA Strategic deal
Preset: Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies. In July 2015 Merck & Co. and Ablynx... Read More
Sun Pharma submitted BLA in USFDA for tildrakizumab to treat plaque psoriasis
Sun Pharmaceutical Industries Ltd, announced the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for tildrakizumab. The... Read More
Saudi Food and Drug Administration (SFDA) has approved Swedish Orphan Biovitrum AB (Sobi)’s Orfadin (nitisinone)
Saudi Food and Drug Administration (SFDA) has approved Swedish Orphan Biovitrum AB (Sobi)’s Orfadin (nitisinone) capsules in all strengths (2 mg, 5... Read More
Pharma Strategic Deal Insight : Boehringer Ingelheim and Peking University (PKU)
Boehringer Ingelheim and Peking University (PKU), has strategic partnership for jointly advancing early science innovation across a range of areas of high... Read More
Otsuka and Teva Sign Licensing Agreement for Japan for Fremanezumab
Posted on15 May 2017
Comments0
Otsuka Pharmaceutical Co., Ltd and Teva Pharmaceutical Industries, Ltd. announce an agreement covering Japan for Otsuka to develop and commercialize Teva’s investigational drug candidate fremanezumab... Read More
Case Study: USFDA Pediatric Disease Designation for Imara’s lead Product Candidate IMR-687 for Sickle Cell Disease
Posted on15 May 2017
Comments0
Imara Inc., a biotechnology company dedicated to developing novel therapeutics for patients with sickle cell disease (SCD) and other hemoglobinopathies, announced today... Read More
Glenmark Pharmaceuticals to Initiate Clinical Study for GBR 1342, Second Investigational New Drug from Immuno-Oncology Portfolio
Glenmark Pharmaceuticals, a global pharmaceutical company, announced that USFDA cleared the company’s Investigational New Drug (IND) application to initiate a Phase 1... Read More